A user experienced severe scalp itching with MPB and found Nizoral ineffective. A doctor diagnosed seborrheic eczema and prescribed Betacap, which relieved the itching.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
After jaw surgery caused intense hair shedding and scalp itch, using pyrilutamide significantly reduced these symptoms. It's suggested to test pyrilutamide for authenticity before use, despite positive personal experience with the product from MV Supplements.
The user is experiencing chronic folliculitis with scalp sores and is concerned about a receding hairline. They have tried various treatments including antibiotics, Nizoral 2% shampoo, and lifestyle changes, but are seeking further advice.
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
The conversation is about a user complaining about the strong smell of a stemoxydine serum used for hair loss. Other users suggest that the product might be counterfeit due to its unpleasant odor.
A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.
The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.
The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.
GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
The user discusses using essential oils like peppermint, rosemary, tea tree, and lavender to improve hair thickness and seborrheic dermatitis. They plan to add RU58841 to their routine and seek advice on using it alongside the essential oils without interference.
A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.
A user found that scalp itch might be linked to inflammation rather than DHT alone and noticed hair improvement with certain cancer drugs. They also discovered that black seed oil relieved their scalp itch and are experimenting with a mix of essential oils for dry scalp, questioning if oils affect minoxidil absorption.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.
A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.
The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.
The user experienced severe hair shedding from RU58841 and recovered by stopping its use and starting treatments including Minoxidil, Rosemary Verbenone, Stemoxydine, Aminexil, copper peptide serum, and specific shampoos. They also consistently used oral Finasteride and plan to try Minoxidil 10%.
RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.
The user is experiencing severe hair loss after starting Minoxidil 5% and is seeking advice, as their hair loss worsened following a second COVID infection. Despite normal hormone and vitamin levels, the user is considering additional treatments like Ketoconazole shampoo, massages, and low-level laser therapy.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.